Search clinical trials for: ranibizumab

Total 621 results

Faculty Hospital Kralovske Vinohrady

Withdrawn

Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation (BEY-RAP)

Wet Macular Degeneration

Czechia
Ocular Therapeutix, Inc.

Active, not recruiting

CLN-0046: Treatment of AMD Subjects With OTX-TKI

Neovascular Age-related Macular Degeneration

Australia
University of California, San Francisco
Genentech, Inc.

Terminated

Ranibizumab in Preventing Failure of Ahmed Valve Glaucoma Surgery

Glaucoma

United States
Peking University People's Hospital

Completed

Efficacy and Safety Comparison of IVR and IVC Before Vitrectomy in Proliferative Diabetic Retinopathy

Proliferative Diabetic Retinopathy

China
Peking University People's Hospital

Completed

Comparison of Surgery Outcome Between Preoperative IVR and Intraoperative IVR in PPV for PDR

Proliferative Diabetic Retinopathy

China
Janssen Research & Development, LLC

Completed

AAVCAGsCD59 for the Treatment of Wet AMD

Wet Age-related Macular Degeneration

United States
Bristol-Myers Squibb

No longer available

Expanded Access for Abatacept

United States, Belgium
Brugmann University Hospital

Completed

Analysis of naïve Patients With Age-related Macular Degeneration Neovascular Type and Treated With Ranibizumab (Lucentis®) in Treat-and-extend at the CHU Brugmann.

Macular Degeneration

Belgium
Xbrane Biopharma AB
Stada Arzneimittel AG

Completed

Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMD (XPLORE)

Macular Degeneration

Israel, Spain, Hungary, United States, Slovakia, Lithuania, Bulgaria, Czechia, Estonia, India, Latvia, Poland, Romania, Russian Federation, Ukraine
Cairo University

Completed

Intravitreal Ranibizumab Versus Its Combination With Dexamethasone in The Treatment of Diabetic Macular Edema

Diabetic Macular Edema

Egypt
Brigham and Women's Hospital
Patient-Centered Outcomes Research Institute; McGill University; VA Boston Healthcare...

Active, not recruiting

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study (CER-4-T2D)

Type2 Diabetes | Renal Disease | Cardiovascular Events

United States
Outlook Therapeutics, Inc.

Completed

A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Age-related Macular Degeneration | Wet Macular Degeneration | Neovascular Age-related Macular Degeneration

United States
Tyrogenex
International Drug Development Institute; SynteractHCR

Terminated

X-82 to Treat Age-related Macular Degeneration

Eye Diseases | Macular Degeneration | Retinal Degeneration | Retinal Diseases | Age-Related Macular Degeneration (AMD) | Exudative Age-related Macular Degeneration | AMD | Macular Degeneration, Age-related, 10

United States
Novartis Pharmaceuticals

Completed

Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)

Age-related Macular Degeneration (AMD)

United States
Novartis Pharmaceuticals

Completed

Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)

Age-related Macular Degeneration (AMD)

United States
National Eye Institute (NEI)

Completed

A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab

Von Hippel-Lindau Syndrome

United States
Jaeb Center for Health Research
National Eye Institute (NEI); Genentech, Inc.

Completed

Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy (Protocol S)

Proliferative Diabetic Retinopathy

United States
Johns Hopkins University

Terminated

Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE) (CAPTURE)

Retinal Vein Occlusion

United States
Bioeq GmbH

Completed

Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration (COLUMBUS-AMD)

Age-related Macular Degeneration (AMD)

France, Italy, Poland, Russian Federation, Spain, United Kingdom, Germany, Hungary, Ukraine, Austria, Czechia, Israel
Centre Hospitalier Régional Metz-Thionville
University of Pecs

Completed

Reading Speed Improvements in Wet-AMD Patients After Ranibizumab Treatment (PAMER)

Wet Macular Degeneration | Ophthalmopathy
Siriraj Hospital

Completed

Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma

Glaucoma, Neovascular

Thailand
Santen Inc.

Completed

Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects

Age-Related Macular Degeneration

United States, Philippines
South Coast Retina Center; Carson, McBeath, Boswell...
Genentech, Inc.; Doheny Image Reading Center; Retina Partners

Completed

The Effect of Intravitreal Ranibizumab on Visual Acuity and Hard Exudate Resolution in the Treatment of Diabetic Macular Edema With Center Involved Edema and Lipid Exudates

Diabetic Macular Edema | Hard Lipid Exudates

United States
Bristol-Myers Squibb

Completed

Effects of Abatacept in Patients With Early Rheumatoid Arthritis (AVERT-2)

Rheumatoid Arthritis

Italy, Sweden, Taiwan, United States, Peru, Germany, Mexico, Japan, Israel, Spain, Czechia, Argentina, Brazil, Colombia, Romania, Australia, France, Poland, Singapore, Russian Federation, South Africa, Canada, United Kingdom, Hungary, C... and more
Samsung Bioepis Co., Ltd.

Completed

A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Age-Related Macular Degeneration

Korea, Republic of, United States, India, Germany, Hungary, United Kingdom, Czechia, Poland, Russian Federation
Outlook Therapeutics, Inc.

Completed

A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Age-related Macular Degeneration | Wet Macular Degeneration | Neovascular Age-related Macular Degeneration

Australia
Universiti Sains Malaysia

Completed

Effects of Ranibizumab in Primary Pterygium Surgery

Patients With Primary Nasal Pterygium

Malaysia
Genentech, Inc.

Completed

Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration (LADDER)

Macular Degeneration

United States
King's College Hospital NHS Trust
King's College London

Completed

A Pharmacokinetic Study: Ranibizumab, Aflibercept and the Effect of Vitrectomy. (VITCLEAR)

Age Related Macular Degeneration

United Kingdom
Chong Kun Dang Pharmaceutical

Completed

A Study To Evaluate CKD-701 and Lucentis® in Patients With Neovascular(Wet) Age Related Macular Degeneration

Neovascular(Wet) Age Related Macular Degeneration

Korea, Republic of
Clearside Biomedical, Inc.

Terminated

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO (TOPAZ)

Macular Edema | Retinal Vein Occlusion

United States, India, Australia, Hungary, New Zealand
Novartis Pharmaceuticals

Completed

Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved Indications (PACIFIC)

Neovascular (Wet) Age-related Macular Degeneration

Germany, Switzerland, Netherlands
Greater Houston Retina Research
Genentech, Inc.

Completed

Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy. (RRR)

Radiation Retinopathy

United States
Federico II University

Completed

OCTA and Polypoidal Choroidal Vasculopathy

Polypoidal Choroidal Vasculopathy

Italy
Opthea Limited

Completed

A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD

Neovascular Age-related Macular Degeneration

United States, Czechia, France, Hungary, Israel, Italy, Latvia, Poland, Spain, United Kingdom
Hoffmann-La Roche

Completed

Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (STAIRWAY)

Macular Degeneration, Age-Related | Neovascularization, Choroidal

United States
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Unknown

601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO)

Central Retinal Vein Occlusion

China
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Unknown

601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO)

Branch Retinal Vein Occlusion

China
Gangnam Severance Hospital
Novartis; Inje University; Severance Hospital; Konkuk University

Completed

Cytokeratin 8 Level in Age-related Macular Degeneration

Age-related Macular Degeneration

Korea, Republic of
King's College Hospital NHS Trust

Completed

Macular EpiRetinal Brachytherapy Versus Lucentis® Only Treatment (MERLOT) (MERLOT)

Macular Degeneration

United Kingdom
Anders Kvanta

Completed

Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen

Central Retinal Vein Occlusion

Sweden
St. Erik Eye Hospital

Unknown

Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion

Branch Retinal Vein Occlusion With Macular Edema

Sweden
Palmetto Retina Center, LLC

Completed

A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema (TREX-DME)

Diabetic Macular Edema

United States
Hoffmann-La Roche

Completed

A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) (AVENUE)

Choroidal Neovascularization

United States
Oklahoma State University Center for Health Sciences
Novartis

Completed

Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration

Choroidal Neovascularization | Age-Related Maculopathy

United States
Justis Ehlers
Genentech, Inc.

Completed

Safety and Efficacy of Ranibizumab for Diabetic Macular Edema (REACT)

Diabetic Macular Edema

United States
He Eye Hospital

Unknown

Diabetic Macular Edema (DME) Treatment With Ranibizumab and Dexamethasone or Ranibizumab Only.

Macular Edema

China
Southeast Clinical Research Associates, LLC
Genentech, Inc.

Completed

Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF

Exudative Age Related Macular Degeneration

United States
Novartis Pharmaceuticals

Terminated

Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase (CONSTELLATION)

Diabetes | Macular Degeneration | Macular Edema

France
Kapil Kapoor

Completed

Ziv-aflibercept Efficacy in Better Regulating AMD (ZEBRA)

Wet Macular Degeneration | Wet Age-related Macular Degeneration

United States

Search clinical trials for: ranibizumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations